Atlas Trials

An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical trial NCT01532700 · COMPLETED

Trial details

NCT number
NCT01532700
Sponsor
University Health Network, Toronto
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia (CLL)
Start date
2012-02-01
Primary completion
2017-06-30
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.